Alto Neuroscience, Inc. (ANRO) Financials

ANRO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 276.3 million 32.9 million
Dec. 31, 2025 184.7 million 33.5 million
Sept. 30, 2025 147.0 million 35.4 million
June 30, 2025 157.9 million 34.5 million

ANRO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -27.6 million 2.8 million
Dec. 31, 2025 -11.5 million 1.9 million
Sept. 30, 2025 -9.9 million 2.2 million
June 30, 2025 -13.8 million 2.0 million

ANRO Net Income

No data available :(

ANRO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 263.8 million 3.6 million 4.9 million
Dec. 31, 2025 176.5 million 18.4 million 3.8 million
Sept. 30, 2025 137.8 million 22.4 million 5.1 million
June 30, 2025 147.6 million 22.1 million 4.2 million

ANRO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 32.9 million
Dec. 31, 2025 31.9 million
Sept. 30, 2025 27.1 million
June 30, 2025 27.1 million

ANRO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 556000 20.3 million 6.8 million -
Dec. 31, 2025 - 12.0 million 5.1 million -
Sept. 30, 2025 - 10.5 million 4.4 million -
June 30, 2025 - 13.1 million 5.6 million -

ANRO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 184000
Dec. 31, 2025 - 157000
Sept. 30, 2025 - 164000
June 30, 2025 - 100000

ANRO

Price: $26.78

52 week price:
2.29
28.44

Earnings Per Share: -2.43 USD

Exchange: NYQ

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 899.1 million

Links: